Glaxo CEO Sees ‘Stretched’ Valuations in Pharmaceutical M&A: FT
2015-05-11 19:39:20.316 GMT
By Jim Silver
(Bloomberg) -- Low interest rates cause “a discipline
reduction,” increasing “the probability of people making poor
choices,” CEO Andrew Witty says in interview, according to FT.
* “Some of these valuations look stretched,” Witty says
* Witty declines to cite specific deals as examples
* Glaxo won’t “get drawn into the idea that just because
money is cheap we can do anything”
* Story link
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Jim Silver in New York at +1-212-617-7342 or
jsilver@bloomberg.net
To contact the editors responsible for this story:
Andrea Snyder at +1-202-624-1831 or
asnyder5@bloomberg.net
Robin Stringer
2015-05-11 19:39:20.316 GMT
By Jim Silver
(Bloomberg) -- Low interest rates cause “a discipline
reduction,” increasing “the probability of people making poor
choices,” CEO Andrew Witty says in interview, according to FT.
* “Some of these valuations look stretched,” Witty says
* Witty declines to cite specific deals as examples
* Glaxo won’t “get drawn into the idea that just because
money is cheap we can do anything”
* Story link
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Jim Silver in New York at +1-212-617-7342 or
jsilver@bloomberg.net
To contact the editors responsible for this story:
Andrea Snyder at +1-202-624-1831 or
asnyder5@bloomberg.net
Robin Stringer